查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988144

心臟辅助设备市场：2026-2032年全球市场预测（按产品类型、操作模式、治疗持续时间、临床应用和最终用户划分）

Cardiac Assist Devices Market by Product Type, Mode Of Operation, Therapy Duration, Clinical Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，心臟辅助设备市场价值将达到 16.5 亿美元，到 2026 年将成长到 17.5 亿美元，到 2032 年将达到 26.3 亿美元，复合年增长率为 6.84%。

主要市场统计数据
基准年 2025 16.5亿美元
预计年份：2026年 17.5亿美元
预测年份 2032 26.3亿美元
复合年增长率 (%) 6.84%

全面部署心臟辅助设备，重点关注临床进步、技术融合以及相关人员的策略重点。

心臟辅助装置已从一种小众的救命疗法发展成为现代晚期心臟衰竭治疗的核心要素。过去20年间，装置小型化、手术技术和术后护理的进步改变了临床预期，并扩大了可从机械循环支持中获益的患者群体。同时，影像学、血流动力学监测和抗凝血治疗管理的进步进一步提高了手术安全性，使得更早、更果断的临床介入成为可能。

对正在重塑心臟辅助设备创新和医疗保健服务的技术、临床和报销制度变革的融合进行了详细分析。

由于技术、临床实践和卫生经济学等多面向因素的融合，心臟辅助装置领域正经历着变革性的转变。帮浦组件的小型化和经皮入路技术的改进，拓展了微创辅助性治疗的适应症，使急性补偿患者能够早期疗育，并提供可在传统手术室外进行的过渡治疗策略。同时，临床医师正基于风险分层工具和生物标记的进步，重新思考患者选择标准，从而实现更个人化的装置选择和治疗时机。

2025年美国关税调整的累积分析及其对心臟辅助设备供应链和筹资策略的策略影响

美国宣布的2025年一系列关税调整将对整个心臟辅助设备生态系统的供应链设计、采购决策和筹资策略产生实际影响。依赖国际供应链采购精密组件、泵浦组件或专用耗材的製造商，如果无法自行承担或将关税增加的成本转嫁给买家，其利润率可能会面临压力。因此，医疗系统和集团采购组织的采购团队将更严格地审查总交付成本，而供应商也将重新审视合约条款和对冲策略以管理风险。

关键细分洞察，阐明产品类型、运作模式、临床应用、治疗持续时间以及实施过程中对最终用户的影响。

严谨的细分框架阐明了产品系列、运作模式、临床目标、治疗时间长度和最终用户如何相互作用，从而影响部署路径和研发优先顺序。根据产品类型，设备类别涵盖双心室辅助装置、左心室辅助装置、经皮心室辅助装置、右心室辅助装置和人工心臟，经皮辅助装置又可根据 Impella 和 TandemHeart 等平台进一步细分。每个产品类型都有其独特的应用情境、手术流程和服务预期，这些因素都会影响医疗机构确定部署优先顺序。

一份全面的区域性洞察报告，概述了监管、报销和临床生态系统方面的差异如何影响全球心臟辅助设备的采用。

区域趋势对监管方式、报销框架、临床医生诊疗模式和供应链设计产生显着影响，从而为医疗器材的商业化和推广应用开闢了独特的路径。在美洲，先进的心臟中心持续推动微创和永续支援策略的早期应用，这得益于完善的临床註册登记系统、不断完善的保险政策以及丰富的专业外科技术。这种环境正在推动相关技术的发展，这些技术在改善临床疗效和降低再入院率方面展现出显着优势。

企业级策略洞察，揭示设备开发公司在产品创新、合作伙伴关係和不断演变的服务模式方面的趋势。

关键产业相关人员正在采取互补策略，包括产品创新、服务拓展以及与临床中心建立合作关係，以加速实证医学证据的产生和应用。领先的医疗设备製造商正投资于帮浦设计、生物相容性材料和整合感测技术的迭代改进，以减少併发症并简化植入过程。同时，外科医疗设备专家和经导管治疗创新者正在探索混合技术和简化的入路平台，以降低手术复杂性并扩大可进行此类手术的医生范围。

为产业领导者提供可操作的建议，以提高产品相关性、供应链韧性、证据产生和服务型经营模式。

产业领导者应优先考虑一系列切实可行的倡议，以在采购环境有限的情况下，维持临床有效性、保护利润率并加快产品部署。首先，他们应投资于模组化产品策略，实现关键子系统（例如控制器和感测器）的分阶段升级，从而减少整套系统更换的需求，同时提升医院的生命週期价值。其次，他们应制定全面的证据计划，该计划不仅涵盖关键临床试验，还包括註册研究、真实世界临床结果以及直接解决支付方和医院采购疑虑的卫生经济学分析。

一种透明且多方面的调查方法，结合了与临床医生的直接访谈、註册分析、监管审查和基于情境的评估。

本调查方法整合了多种证据来源，以确保为临床、商业和监管相关人员提供可操作、可靠且可重复的见解。主要研究包括对心臟外科医生、心臟衰竭专家、介入性心臟病专家和采购经理进行结构化访谈，以收集关于器械性能、手术流程和推广障碍的实际观点。这些定性资讯将与临床文献综述、同行评审的试验结果和器械註册资讯进行交叉比对，以检验不同器械类别和临床应用中的疗效和安全性特征。

简明扼要的结论整合了技术进步、当前供应链状况、对临床路径的影响以及相关人员。

综合上述分析，心臟辅助装置领域技术蓬勃发展，但运作复杂，多种相互依存的因素共同影响短期选择和长期策略。经经皮输送和连续流架构的技术进步正在拓展手术可能性，并重塑临床决策。同时，数据驱动的护理模式正在改变植入后的预期，并为装置本身以外的附加价值服务创造机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 心臟辅助设备市场：依产品类型划分

  • 双心室辅助装置
  • 左心室辅助装置
  • 经皮心室辅助装置
    • 叶轮
    • 串联心臟
  • 右心室辅助装置
  • 人工心臟

第九章 心臟辅助设备市场：依运作模式划分

  • 连续流
    • 轴流式
    • 圆神流
  • 脉衝流

第十章：按治疗持续时间分類的心臟辅助设备市场

  • 长期
  • 短期

第十一章 依临床应用分類的心臟辅助设备市场

  • 弥合復苏差距
  • 弥合移植差距
  • 最终治疗

第十二章 心臟辅助设备市场：依最终用户划分

  • 医院
  • 专科诊所

第十三章 心臟辅助设备市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 心臟辅助设备市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 心臟辅助设备市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国心臟辅助设备市场

第十七章：中国心臟辅助设备市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AlivCor Inc.
  • Bardy Diagnostics, Inc.
  • Berlin Heart GmbH
  • BiVACOR Inc.
  • Boston Scientific Corporation
  • Cardiac Insight, Inc.
  • Cardiobridge GmbH
  • CorInnova, Inc.
  • CorWave SA
  • GE HealthCare Technologies Inc.
  • Getinge AB
  • Hill-Rom Holdings, Inc.
  • Jarvik Heart Inc.
  • Koninklijke Philips NV
  • LivaNova PLC
  • Medtronic PLC
  • OSI Systems, Inc.
  • Supira Medical
  • Teleflex Incorporated
  • Terumo Corporation
  • Xenios AG
Product Code: MRR-F97DD5A7DF05

The Cardiac Assist Devices Market was valued at USD 1.65 billion in 2025 and is projected to grow to USD 1.75 billion in 2026, with a CAGR of 6.84%, reaching USD 2.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.65 billion
Estimated Year [2026] USD 1.75 billion
Forecast Year [2032] USD 2.63 billion
CAGR (%) 6.84%

Comprehensive introduction to cardiac assist devices highlighting clinical evolution, technology convergence, and strategic priorities for stakeholders

Cardiac assist devices have evolved from niche rescue therapies into central components of contemporary advanced heart failure management. Over the past two decades, improvements in device miniaturization, surgical technique, and postoperative care have shifted clinical expectations and broadened the pool of patients who may benefit from mechanical circulatory support. Concurrent advances in imaging, hemodynamic monitoring, and anticoagulation management have further increased the procedural safety profile, enabling earlier and more decisive clinical interventions.

Clinicians now integrate device selection and timing into multidisciplinary care pathways that include heart failure specialists, cardiac surgeons, intensivists, and rehabilitation teams. This integrated model emphasizes patient-centered endpoints such as functional recovery, quality of life, and reduction of rehospitalizations alongside traditional survival metrics. Device developers have responded with modular product families, hybrid approaches bridging temporary to durable support, and user-centered incremental innovations that reduce implantation complexity.

Regulators and payers have likewise adapted, instituting evidence frameworks and real-world data collection that inform reimbursement sequences and coverage policies. Consequently, technology developers must now navigate not only engineering and clinical hurdles but also the expanding expectations of health systems for demonstrable outcomes. As stakeholders assess strategic options, understanding the interplay between clinical need, device capability, and system-level constraints becomes critical for making informed decisions about investment, adoption, and clinical protocol evolution.

In-depth analysis of converging technological, clinical, and reimbursement shifts reshaping cardiac assist device innovation and care delivery

The landscape for cardiac assist devices is undergoing transformative shifts driven by converging forces across technology, clinical practice, and health system economics. Miniaturization of pump components and the refinement of percutaneous access techniques have expanded indications for less invasive support, enabling earlier intervention in acutely decompensated patients and offering bridge strategies that can be deployed outside traditional operating rooms. Concurrently, clinicians are recalibrating patient selection criteria based on improved risk stratification tools and biomarkers, which has led to more personalized device choices and therapy timing.

In parallel, data-driven monitoring and remote telemetry have redefined post-implant care, facilitating outpatient management protocols and reducing hospital length of stay. These capabilities have important implications for device design and service models, shifting some value propositions from device durability alone toward integrated solutions encompassing remote monitoring, predictive maintenance, and digital care workflows. Reimbursement models are adapting, with increasing emphasis on bundled care outcomes and value-based arrangements that prioritize quality metrics and total cost of care rather than procedural volume.

Finally, the competitive landscape is evolving as established implantable device manufacturers, surgical device specialists, and new entrants with expertise in transcatheter systems converge. This competitive convergence has intensified partnerships, licensing agreements, and targeted acquisitions intended to bridge gaps across therapy duration, access modality, and clinical application. As a result, stakeholders must adopt adaptive strategies that anticipate continued technological refinement and shifting care delivery expectations.

Cumulative analysis of 2025 United States tariff adjustments and their strategic implications for cardiac assist device supply chains and procurement strategies

The set of tariff adjustments announced for 2025 in the United States introduces tangible implications for supply chain design, sourcing decisions, and procurement strategy across the cardiac assist device ecosystem. Manufacturers that rely on international supply chains for precision components, pump assemblies, or proprietary consumables may experience margin compression if tariff-induced cost increases cannot be absorbed or passed through to purchasers. Consequently, procurement teams within health systems and group purchasing organizations are likely to scrutinize total delivered cost more closely, while suppliers may revisit contract terms and hedging strategies to manage exposure.

These tariff adjustments also affect strategic manufacturing footprints. Some companies will consider nearshoring critical components or expanding domestic manufacturing capacity to mitigate tariff sensitivity and improve supply continuity. Such shifts require capital allocation, regulatory revalidation of production sites, and potential reconfiguration of logistics networks, all of which have lead times that extend beyond immediate procurement cycles. In the near term, contractual renegotiation and volume-based sourcing arrangements will be important levers for both suppliers and buyers to preserve access and control pricing volatility.

Clinicians and hospital administrators should anticipate potential downstream effects on device availability and value-based contracting. To navigate this environment, cross-functional teams that include supply chain, clinical leadership, and contracting specialists should develop scenario plans that balance short-term operational continuity with long-term strategic resilience. By doing so, organizations can protect patient access to critical therapies while positioning themselves to benefit from supply chain optimization opportunities that arise from tariff-driven adjustments.

Key segmentation insights that delineate product types, operational modalities, clinical applications, therapy durations, and end-user implications for adoption

A rigorous segmentation framework clarifies how product families, operational modes, clinical intent, therapy duration, and end users interact to shape adoption pathways and development priorities. Based on product type, device categories range from biventricular assist devices and left ventricular assist devices to percutaneous ventricular assist devices, right ventricular assist devices, and total artificial hearts, with percutaneous options further differentiated by platforms such as Impella and TandemHeart; each product category presents distinct clinical use cases, procedural workflows, and service expectations that influence how institutions prioritize adoption.

Based on mode of operation, devices are studied across continuous flow and pulsatile flow technologies, with continuous flow devices further segmented into axial flow and centrifugal flow architectures; these operational distinctions carry implications for hemocompatibility, thrombosis risk, and long-term durability considerations, and therefore influence clinician selection and post-implant management strategies. Based on clinical application, therapeutic roles include bridge to recovery, bridge to transplant, and destination therapy, each with unique registry requirements, outcome endpoints, and patient counseling priorities that affect device evaluation criteria.

Based on therapy duration, understanding contrasts between long-term and short-term use cases helps align product engineering with anticipated clinical pathways and follow-up needs, and based on end user, recognizing differences in utilization across hospitals and specialty clinics clarifies service models, training priorities, and capital acquisition approaches. Together, these cross-cutting segmentation lenses provide a structured way to evaluate technology fit, clinical workflow integration, and long-term support obligations.

Comprehensive regional insights outlining how regulatory, reimbursement, and clinical ecosystem differences shape cardiac assist device adoption across global regions

Regional dynamics significantly influence regulatory approaches, reimbursement paradigms, clinician practice patterns, and supply chain design, creating differentiated pathways for device commercialization and adoption. In the Americas, advanced cardiac centers continue to drive early adoption of minimally invasive and durable support strategies, supported by robust clinical registries, evolving coverage policies, and concentration of specialized surgical expertise; this environment favors technologies that demonstrate clear improvements in clinical outcomes and reductions in rehospitalization burden.

In Europe, the Middle East & Africa, regulatory harmonization efforts and national procurement frameworks shape pricing and access differently across jurisdictions, while pockets of clinical excellence in major metropolitan centers serve as hubs for advanced device adoption and investigator-led trials. Stakeholders operating in these regions must adapt to heterogeneous reimbursement landscapes and develop differentiated engagement strategies for national health services and private payers.

In Asia-Pacific, dynamic healthcare investment, expanding specialty care infrastructure, and rising cardiovascular disease burden create significant demand for scalable device solutions and services. However, regional regulatory timelines, reimbursement design, and local manufacturing preferences can materially affect go-to-market strategies. Across all regions, nuanced approaches to clinician education, local evidence generation, and post-market surveillance are essential to secure durable adoption and to align product support models with regional health system capabilities.

Strategic company-level insights revealing product innovation trends, collaborative partnerships, and service model evolution among device developers

Key industry participants are pursuing complementary strategies that encompass product innovation, service expansion, and collaborative arrangements with clinical centers to accelerate evidence generation and deployment. Leading device manufacturers are investing in iterative improvements to pump design, biocompatible materials, and integrated sensing to reduce complications and simplify implantation. At the same time, surgical device specialists and transcatheter innovators are exploring hybrid techniques and simplified access platforms that lower procedural complexity and broaden the range of eligible operators.

Partnerships between device developers and digital health vendors are increasing to enable remote monitoring, predictive maintenance algorithms, and patient engagement tools that extend the value proposition beyond the implant procedure. Several companies are also expanding service footprints to include training academies, simulation-based operator credentialing, and bundled service offerings that reduce institutional adoption friction. Strategic alliances with large health systems and academic centers are facilitating real-world evidence generation and registry development, which supports clinical guideline incorporation and payer discussions.

Emerging entrants with strengths in minimally invasive delivery or component manufacturing are prompting incumbents to reassess competitive postures, often resulting in licensing agreements or targeted acquisitions. For procurement teams and corporate strategists, tracking these moves provides early signals about future product roadmaps, integration priorities, and potential new service models that could alter procurement criteria and clinical workflows.

Actionable recommendations for industry leaders to enhance product relevance, supply chain resilience, evidence generation, and service-based commercial models

Industry leaders should prioritize a set of actionable initiatives to maintain clinical relevance, protect margins, and accelerate adoption within constrained procurement environments. First, invest in modular product strategies that allow incremental upgrades to key subsystems, such as controllers and sensors, reducing the need for full-system replacement while improving the lifetime value proposition for hospitals. Second, develop comprehensive evidence plans that extend beyond pivotal trials to include registries, real-world outcomes, and health economic analyses that speak directly to payer and hospital procurement concerns.

Third, strengthen supply chain resilience through dual sourcing, nearshoring critical components, and strategic inventory policies to mitigate tariff and logistics-related disruptions. Fourth, expand service offerings to include training, remote monitoring, and lifecycle maintenance programs that reduce institutional barriers to adoption and create recurring revenue streams. Fifth, engage proactively with regulators and payers to clarify evidence expectations and to pilot value-based contracting arrangements that align incentives across stakeholders.

Finally, cultivate clinician partnerships through centers of excellence, investigator-initiated trial support, and co-development arrangements that prioritize user experience and workflow integration. By executing these initiatives in parallel, industry leaders can better align product development with health system demands, buffer against supply chain shocks, and accelerate meaningful clinical uptake.

Transparent and multi-source research methodology combining primary clinician interviews, registry analysis, regulatory review, and scenario-based assessments

The research methodology integrates multiple evidence streams to ensure robust, reproducible insights that are actionable for clinical, commercial, and regulatory stakeholders. Primary research includes structured interviews with cardiac surgeons, heart failure specialists, interventional cardiologists, and procurement leaders to capture frontline perspectives on device performance, procedural workflows, and adoption barriers. These qualitative inputs are triangulated with clinical literature reviews, peer-reviewed trial outcomes, and device registries to validate efficacy and safety characteristics across device categories and clinical applications.

Secondary data sources include regulatory filings, real-world evidence datasets, and technology whitepapers that provide context on device approvals, post-market surveillance findings, and evolving standard-of-care benchmarks. The methodology also uses scenario analysis and sensitivity assessments to explore the operational and financial implications of supply chain disruptions, regulatory changes, and reimbursement shifts. Throughout the process, findings are subjected to internal peer review by clinical and technical experts to ensure interpretive rigor and to minimize bias.

Transparency is maintained by documenting data sources, interview protocols, and analytical assumptions, while confidentiality safeguards protect participating clinicians and institutions. The resulting methodological approach balances depth of clinical validity with practical applicability, enabling stakeholders to translate insights into strategy, trial design input, and procurement planning.

Concise conclusion synthesizing technology advances, supply chain realities, clinical pathway implications, and strategic imperatives for stakeholders

Synthesis of the preceding analyses points to a cardiac assist device environment that is simultaneously technologically vibrant and operationally complex, with multiple interdependent forces shaping near-term choices and long-term strategy. Technological advances in percutaneous delivery and continuous flow architectures are expanding procedural possibilities and recalibrating clinical decision-making, while data-enabled care models are altering post-implant expectations and creating opportunities for value-added services that extend beyond the physical device.

At the same time, supply chain dynamics, including tariff effects and component sourcing decisions, are imposing new considerations on procurement and cost management. Regional regulatory and reimbursement heterogeneity requires differentiated commercialization roadmaps, and company strategies that emphasize partnerships, evidence generation, and service models are likely to be more resilient. For clinical leaders, aligning multidisciplinary care pathways and investing in training will be essential to capture the full potential of these technologies in improving patient-centered outcomes.

Overall, stakeholders who integrate device innovation with robust evidence generation, resilient supply chain planning, and service-oriented commercial approaches will be better positioned to deliver sustained clinical impact and operational value across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Assist Devices Market, by Product Type

  • 8.1. Biventricular Assist Device
  • 8.2. Left Ventricular Assist Device
  • 8.3. Percutaneous Ventricular Assist Device
    • 8.3.1. Impella
    • 8.3.2. TandemHeart
  • 8.4. Right Ventricular Assist Device
  • 8.5. Total Artificial Heart

9. Cardiac Assist Devices Market, by Mode Of Operation

  • 9.1. Continuous Flow
    • 9.1.1. Axial Flow
    • 9.1.2. Centrifugal Flow
  • 9.2. Pulsatile Flow

10. Cardiac Assist Devices Market, by Therapy Duration

  • 10.1. Long Term
  • 10.2. Short Term

11. Cardiac Assist Devices Market, by Clinical Application

  • 11.1. Bridge To Recovery
  • 11.2. Bridge To Transplant
  • 11.3. Destination Therapy

12. Cardiac Assist Devices Market, by End User

  • 12.1. Hospitals
  • 12.2. Specialty Clinics

13. Cardiac Assist Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cardiac Assist Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cardiac Assist Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cardiac Assist Devices Market

17. China Cardiac Assist Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AlivCor Inc.
  • 18.7. Bardy Diagnostics, Inc.
  • 18.8. Berlin Heart GmbH
  • 18.9. BiVACOR Inc.
  • 18.10. Boston Scientific Corporation
  • 18.11. Cardiac Insight, Inc.
  • 18.12. Cardiobridge GmbH
  • 18.13. CorInnova, Inc.
  • 18.14. CorWave SA
  • 18.15. GE HealthCare Technologies Inc.
  • 18.16. Getinge AB
  • 18.17. Hill-Rom Holdings, Inc.
  • 18.18. Jarvik Heart Inc.
  • 18.19. Koninklijke Philips N.V.
  • 18.20. LivaNova PLC
  • 18.21. Medtronic PLC
  • 18.22. OSI Systems, Inc.
  • 18.23. Supira Medical
  • 18.24. Teleflex Incorporated
  • 18.25. Terumo Corporation
  • 18.26. Xenios AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC ASSIST DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARDIAC ASSIST DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY IMPELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY IMPELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY IMPELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TANDEMHEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TANDEMHEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TANDEMHEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY AXIAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY AXIAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY AXIAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CENTRIFUGAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CENTRIFUGAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CENTRIFUGAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PULSATILE FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PULSATILE FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY PULSATILE FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LONG TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LONG TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY LONG TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SHORT TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SHORT TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SHORT TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO RECOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO RECOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO RECOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 142. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 143. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 164. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 165. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 166. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 167. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 173. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 174. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 175. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIAC ASSIST DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY PERCUTANEOUS VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY MODE OF OPERATION, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY CONTINUOUS FLOW, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY THERAPY DURATION, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA CARDIAC ASSIST DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)